Company intelligence / Profile preview

KM Biologics

Ownership: Private
Development stage: Commercial

Overview

KM Biologics has a long history in vaccine production with commercialized products for both human and veterinary use. The company has contributed significantly to infectious disease control in Japan. No current active clinical trials are registered on ClinicalTrials.gov as of May 2025.

Therapeutic areas: Infectious Diseases
Modalities: Vaccines (human and veterinary)Blood plasma productsCell culture-derived vaccinesCombination vaccines (e.g., DPT-based)
Industry: Biotech

Drug pipeline

22 assets

Aimmugen

Unknown

21 more assets in the full pipeline.

Request access →

Partnerships

Collaborates with companies and universities domestically and internationally for new vaccine development.

Beyond the preview

Go deeper on KM Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KM Biologics.

Explore the full profile